RxDoctor Payments Data

Sander Dorfzaun

Optometrist · Marietta, GANPI 1699804120

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,830 of the $10,045 with a category attached, or 78.0%. Visioneering Technologies, Inc. accounts for 78.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $8,031 and has fallen 93.8% since, to $495 in 2025. Among optometrist clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,045in general payments, 2019–2025

Across 81 payments — averaging $124.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Visioneering Technologies, Inc.$8K
  • Alcon$311
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$299
  • Bausch & Lomb Americas Inc.$248
  • Sun Pharmaceutical Industries Inc.$232
  • Tarsus Pharmaceuticals, Inc.$170
  • plus $936 from 14 others

What the payments were for

  • Speaking & faculty fees$7,83078%
  • Food & beverage$2,20822%
  • Entertainment$70%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,045 in reported general payments places this provider in the 95th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$96,562
Medicare patients
434
Services billed
3,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine13$15,623
XiidraLifitegrast13$10,314
Latanoprost118$1,044
Timolol Maleate51$368
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$301
Brimonidine Tartrate34$193
Cephalexin16$81
Dorzolamide Hcl20$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$100$15,62313 claims
Bausch & Lomb Americas Inc.Xiidra$248$10,31413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →